Is a complete XLO research report available?

No complete published report is available for Xilio Therapeutics, Inc. (XLO) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · USD

$8.65

+0.34 (+4.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-25 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first XLO analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	51.8M
Revenue (ttm)	53.5M
Net income (ttm)	-31.3M
EPS (ttm)	-$5.41
Shares out	6M
Volume	20,074
Beta	-0.12

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 53.5M
Net income (ttm): -31.3M
EPS (ttm): -$5.41
Market cap: 51.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All XLO indicators

Market & fundamental data

Available fields

194

Groups with data

Currency

USD

Showing 194 of 194 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001840233
Company name	Xilio Therapeutics, Inc.
Country	United States
Country code	US
Cusip	98422T209
Employees	76
Employees Change	12%
Employees Change Percent	18.75
Enterprise value	$-91.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-10-22
Isin	US98422T2096
Last refreshed	2026-07-25
Market cap	$51.8M
Market cap category	Micro-Cap
Price	$8.65
Price currency	USD
Rev Per Employee	703,736.84x
Sector	Healthcare
Sector PE	44.87
Sector PE Fwd	23.76
Sic	2834
Symbol	XLO
Website	https://xiliotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-60.48%
FCF yield	-110.85%
P/B ratio	0.69x
P/S ratio	0.97x
PS Forward	2.22x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-78.98%
EBITDA Margin	-76.39%
Gross margin	79.13%
Gross Profit	$42.3M
Gross Profit Growth	2,929.42%
Net Income	$-31.3M
Net Income Growth Quarters	2%
Net Income Growth Years	3%
Pretax Margin	-58.52%
Profit Margin	-58.52%
Profit Per Employee	$-411,842
ROA	-19.76
Roa5y	-39.45
ROCE	-35.05
ROE	-75.2
Roe5y	-119.7
ROIC	-54.02

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-10.4%
Cagr3y	-39.92%
EPS Growth Quarters	12
EPS Growth Years	5
Revenue Growth	476.71x
Revenue Growth Q	331.67x
Revenue Growth Quarters	4x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.4
Assets	$163.5M
Cash	$150.3M
Current Assets	$154.2M
Current Liabilities	$43M
Debt	$6.6M
Debt Equity	$0.09
Equity	$72.5M
Liabilities	$90.9M
Long Term Assets	$9.3M
Long Term Liabilities	$48M
Net Cash	$143.7M
Net Cash By Market Cap	$278
Net Cash Growth	76.94%
Net Debt Equity	$-1.98
Tangible Book Value	$72.5M
Tangible Book Value Per Share	$12.55
WACC	3.17

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.59
Net Working Capital	$-37.7M
Quick ratio	3.5
Working Capital	$111.2M
Working Capital Turnover	$0.68

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-24.15%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-10.39%
200-day SMA	8.98
3Y total return	-78.32%
50-day SMA	8.62
50-day SMA vs 200-day SMA	50under200
All Time High	391.3
All Time High Change	-97.79%
All Time High Date	2021-11-16
All Time Low	6.47
All Time Low Change	33.8%
All Time Low Date	2026-03-12
ATR	0.43
Beta	-0.12
Beta1y	0.25
Beta2y	0.28
Ch YTD	-3.49
High	8.65
High52	12.74
High52 Date	2025-09-30
High52ch	-32.1%
Low	8.33
Low52	6.47
Low52 Date	2026-03-12
Low52ch	33.8%
Ma50ch	0.34%
Price vs 200-day SMA	-3.71%
RSI	46.78
RSI Monthly	31.86
RSI Weekly	49.8
Sharpe ratio	-0.08x
Sortino ratio	0
Total Return	-24.15%
Tr YTD	-3.49
Tr1m	-2.81%
Tr1w	-2.59%
Tr3m	2.13%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Earnings EPS Estimate	$-0.59
Earnings Revenue Estimate	12,720,000x
Earnings Revenue Estimate Growth	57.35x
Operating Income	$-42.2M
Operating margin	-78.98

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,752,105%
Float Percent	62.71%
Shares Insiders	8.99%
Shares Institutions	19.55%
Shares Out	5,982,839
Shares Qo Q	27.63%
Shares Yo Y	24.15%
Short Float	4.65%
Short Ratio	4.84
Short Shares	2.92

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-65M
Average Volume	56,402.55x
Bv Per Share	12.55
CAPEX	$-1.1M
Ch1m	-2.81
Ch1w	-2.59
Ch1y	-10.39
Ch3m	2.13
Ch3y	-78.32
Ch6m	-1.74
Change	4.09%
Change From Open	2
Close	8.31
Days Gap	2.05
Depreciation Amortization	1,388,000
Dollar Volume	173,640.1
Earnings Date	2026-08-13
Earnings Time	bmo
EBIT	$-42.2M
EBITDA	$-40.9M
EPS	$-5.41
F Score	3
FCF	$-57.4M
FCF EV Yield	62.39x
FCF Per Share	$-9.59
Financing CF	118,650,000
Fiscal Year End	December
Founded	2,016
Investing CF	-1,052,000
Ipr	-45.94
Iprfo	-95.88
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Date	2026-03-16
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	8.41
Ma150ch	2.82%
Ma20	9.03
Ma20ch	-4.22%
Net CF	61,285,000
Next Earnings Date	2026-08-13
Open	8.48
Optionable	No
Position In Range	100
Post Close	8.65
Postmarket Change Percent	1.97
Postmarket Price	$8.82
Ppne	7,467,000
Price Date	2026-07-24
Ptbv Ratio	0.71
Relative Volume	0.36x
Revenue	53,484,000x
SBC By Revenue	14.24x
Share Based Comp	7,615,000
Tr6m	-1.74%
Us State	Massachusetts
Volume	20,074
Z Score	-3.12

Xilio Therapeutics, Inc. (XLO)

Coverage state: Market snapshot only — no published research

Generate the first XLO analysis

Price

Financial snapshot

Fair-value bridge

Latest news · XLO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XLO indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on XLO

Frequently asked questions